Propel Antibody-Drug Conjugate Therapy Development with Clinical Trial Ready Immunohistochemistry Assays
Good Antibody-drug conjugate (ADC) therapy development decisions start with dependable research, and in the challenging, competitive pharmaceutical market, that means accurate, reliable testing protocols and results. In this webinar, Dr. Frank Lynch, EVP, Global Tissue Biomarker Services and Dr. Suso Platero, Chief Scientific Officer, at Discover Life Sciences will share insights about the ADC market and discuss why adopting a robust, sensitive, and specific biomarker assay alongside ADC therapy development is critical to success in clinical trials.
Frank Lynch, Ph.D., Executive Vice President, Global Tissue Biomarker Services
Discovery Life Sciences
For more than 30 years Dr. Frank Lynch has been a pioneer in immunohistochemistry (IHC) applications in research and clinical studies. Frank co-founded QualTek Molecular Laboratories in 1997 and developed an IHC services platform built around this powerful tool that allows for the understanding of expression and localization of specific proteins with cell and sub-cellular specific resolution. Frank has worked with hundreds of biopharma companies and oncology groups. He has overseen over 1,500 studies and hundreds of oncology clinical studies using IHC biomarkers, including the development of a crucial, high profile, PD-L1 prototype companion diagnostic test. QualTek recently merged with Discovery Life Sciences where Frank now serves as Executive Vice President, Global Head of Sales Services. Prior to QualTek, Frank helped grow start-up company BioTek Solutions (later merging with Ventana) where he assisted in automating clinical IHC assays in hundreds of hospitals and anatomic pathology labs around the world. At BioTek, he developed the first widely accepted automated IHC test for estrogen receptor (H222 clone) in FFPE breast cancer using the TechMate immunostainer. Frank received his PhD from Rutgers University / UMDNJ, where he researched dUTPase and its role in patient response to 5FU in colorectal cancer.
Suso Platero, Ph.D., Chief Scientific Officer, Discovery life Sciences
Suso J. Platero, Ph.D., joined the company as its chief scientific officer in September 2022. He has over 25 years of executive leadership in building and managing biomarker development organizations at leading pharmaceutical and diagnostics companies with an acute focus on personalized medicine.
Dr. Platero’s extensive experience in precision medicine, oncology, and diagnostic and drug development enhances Discovery’s genomic, proteomic, and cell-based tissue biomarker services, as well as the company’s market-leading cell and gene therapy (CGT) product and service offerings. His responsibilities include scientific strategy of the company, collaborating with academic and industry leaders, and developing new technologies to help our clients achieve success in their global clinical trials.
Before joining Discovery, Dr. Platero served as vice president of biomarkers, imaging, and diagnostics at Vertex Pharmaceuticals. Prior to Vertex, he designed and led the development of a Biomarker Solution Center for Cell and Gene Therapy, Immuno-Oncology, and Oncology at Labcorp. Additionally, his prior experience includes management of oncology translational research teams at the Janssen Pharmaceutical Companies of Johnson & Johnson and the Clinical Biomarkers team at Bristol-Myers Squibb.